DEC 0 1 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF: Kozlowski *et al.*

Examiner: Acquah, S.

SERIAL NO.:

10/734,858

Group Art Unit: 1711

FILED:

December 11, 2003

Confirmation No. 1526

FOR: SEGMENTED POLYMERS AND THEIR

CONJUGATES

Information Disclosure Statement After First Office Action but Before Final Action or Notice of Allowance-37 CFR 1.97(c)

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed after three months of the filing date of this application or after the mailing date of the first office action on the merits, whichever occurred last, but before the mailing date of either a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

	Copies of the following references are enclosed: ☐ References marked with a double asterisk (**). ☐ References marked by asterisks ☑ All cited references except U.S. patents and/or published applications (See C.F.R. § 1.98(a)(2)(i)).						
☐ Appli☐ ☐ ☐ ☐ ☐	Copies of the following references can be found in parent U.S. cation No. *: All cited references References marked with a single asterisk (*). The following:						
unde comn	The following reference is not in English. For each such reference, the undersigned has enclosed: (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference; (iii) a copy of a reference which appears to be an English-						

language counterpart; or (iv) an English-language abstract for the reference

	prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.
	 ☐ All cited references ☐ References marked by ampersands ☐ The following:
3.	Effect of Information Disclosure Statement (37 CFR 1.97(h)) This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.
4.	Fee Payment ☐ Applicant elects to pay the fee under 37 CFR 1.17(p) in the amount of \$180.00. ☐ Enclosed is a check for \$180 in payment of the fee due.
	☑ The Commissioner is hereby authorized to charge any deficiency in fees to ensure timely submission of these papers to Deposit Account No. 50-2207.
5.	Patent Term Adjustment (37 CFR 1.704(d)) The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).
	Respectfully submitted, Perkins Coie LLP
Date:	2c. (, 2005 LeeAnn Gorthey

Correspondence Address:

Customer No. 22918 Tel: 650 838-4403

LeeAnn Gorthey Registration No. 37,337

COMPLETE IF KNOWN 10/734.858 Application Number INFORMATION DISCLOSURE Confirmation Number STATEMENT BY APPLICANT Form PTO-1449 (Modified) DEC 0 1 7005 (Use several sheets if necessary) 1526 Filing Date December 11, 2003 First Named Inventor Kozlowski et al. Group Art Unit 1711 Examiner Name Acquah, S. Sheet of 3 Attorney Docket No. 41714.8001

TO PAPE	MARY	/			U.S	. PATENT DOCUME	NTS	3			
Examiner Initials*	Cite U.S. Patent or Application No. NUMBER Kind Code				Name of Patentee or Inventor of Cited Document		Date of Publication or Filing Date of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1	467	4670417			lwasaki et al.		06/1987			
	2	525	2714		Harris et al.		10/1993				
	3	528	1698		Nit	ecki.		01/1994			
1	4	546	8478		Sa	Saifer et al.		11/1995			
	5	565	0234		Do	lence et al.		07/1997 09/1997 10/1998 05/1999 08/1999			
	6	567	2662		На	rris <i>et al</i> .					
	7	582	4784		Kir	istler <i>et al</i> .					
	8	590	0461		На	rris.					
	9	593	2462		На	rris <i>et al.</i>					
	10	634	8558		Harris et al.			02/2002			
										,	
				F	ORE	IGN PATENT DOCU	MEN	NTS			
Examiner Initials*	Cite No.	Fo Office	oreign Patent or App	Kind	Code	Name of Patentee or Applicant of Cited Document		Date of Publication or Filing Date of Cited Document		Pages, Columns, Lines, here Relevant Passages or Relevant Figures Appear	Т
	11	PCT	WO 99/459	64			09	9/1999			
	12	PCT	WO 01/266	692			04	-/2001			
12 1 01 11 01 12 01 1											
			OTHER P	RIOR A	ART-	NON PATENT LITER	RATI	URE DOCUMEN	ГS		
Examiner Initials*	Cite No.	(book,				or (in CAPITAL LETTERS), tit catalog, etc.), date, page(s), v					ed.
	Abuchowski et al., "Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates," Cancer Biochem. Biophys,										
	13			krom	ol (Chem., 179 :301 - 31	2 (1978)			
	14		<u>`</u>						Glv	col-Protein Adducts:	
	15	Beauchamp <i>et al.</i> , "A New Procedure for Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and α2-Macroglobulin," <i>Analytical Biochemistry</i> , 131 :25-33 (1983).									

EXAMINER		DATE CONSIDERED			
*EXAMINER:	R: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).				

COMPLETE IF KNOWN ٠<u>٨</u> 10/734.858 Application Number **INFORMATION DISCLOSURE** Confirmation Number 1526 STATEMENT BY APPLICANT Filing Date December 11, 2003 Form PTO-1449 (Modified) First Named Inventor Kozlowski et al. (Use several sheets if necessary) Group Art Unit 1711 Acquah, S. Examiner Name Sheet of 3 Attorney Docket No. 41714.8001

16	Brinkley, M. A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents. <i>Bioconjug. Chem.</i> 3 :2-13 (1992).
17	Buckman et al., "Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol)," <i>Makromol. Chem.</i> , 182 :1379-1384 (1981).
18	Duncan, R.J., Weston, P.D., Wrigglesworth, R. A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. <i>Anal. Biochem.</i> 132 (1):68-73 (1983).
19	Elling et al., "Immunoaffinity Partitioning: Synthesis and Use of Polyethylene Glycol-Oxirane for Coupling to Bovine Serum Albumin and Monoclonal Antibodies," Biotechnology and Applied Biochemistry, 13:354-362 (1991).
20	Goodson et al., "Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site," Bio/Technology, 8(4):343-346, (1990).
21	Greenwald et al., "Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates," J. Org. Chem., 60:331-336 (1995).
22	Harris et al., "Synthesis and Characterization of Poly(ethylene glycol) Derivatives," J. Polym. Sci. Chem. Ed., 22:341-352 (1984).
23	Joppich et al., "Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups," Makromol. Chem., 180:1381-1384 (1979).
24	Kogan, "The Synthesis of Substituted Methoxy-Poly(ethylene glycol) Derivatives Suitable for Selective Protein Modification," <i>Synthetic Communications</i> , 22 (16):2417-2424 (1992).
25	Mattson, G., Conklin, E., Desai, S., Nielander, G., Savage, M.D. and Morgensen, S. A practical approach to crosslinking. <i>Mol. Biol. Rep.</i> 17 (3):167-183 (1993).
26	Means, G.E. and Feeney, R.E. Chemical modifications of proteins: history and applications. <i>Bioconjug. Chem.</i> 1 :2-12 (1990).
27	Okamoto <i>et al.</i> , "Kinetic Study on Reactions Between Polymer Chain-EndsII. Reactions Between Chlorosulphonyl-Ended and Primary Amino-Ended Polyoxyethylenes Followed by Fluorometry", <i>Eur. Polym. J.</i> , 19 (4):341-346 (1983).
28	Pitha et al., "Detergents Linked to Polysaccharides: Preparation and Effects on Membranes and Cells," Eur. J. Biochem., 94 :11-18 (1979).
29	Sartore et al., "Enzyme Modification by MPEG with an Amino Acid or Peptide as Spacer Arms," Applied Biochemisty and Biotechnology, 27 :45-54 (1991).

EXAMINER		DATE CONSIDERED		
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not			
	considered. Include copy of this form with next communication to a	pplication(s).		

4				COMPLETE IF KNOWN			
· ·	INFORMATION	DISCLOSURE		Application Number	10/734.858		
				Confirmation Number	1526		
	STATEMENT	BY APPLICANT		Filing Date	December 11, 2003		
	Form PTO-14	149 (Modified)		First Named Inventor	Kozlowski et al.		
	(Use several she	ets if necessary)		Group Art Unit	1711		
				Examiner Name	Acquah, S.		
Sheet	3	of	3	Attorney Docket No.	41714.8001		

30	Sawhney et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylen glycol)-co-poly(α -hydroxy acid) Diacrylate Macromers," <i>Macromolecules</i> , 26 :581-587 (1993).
31	Tondelli et al., "Poly(Ethylene Glycol) Imidazolyl Formates as Oligomeric Drug-Binding Matrices," Journal of Controlled Release, 1:251-257 (1985).
32	Veronese et al., "Activation of Monomethoxy-Polyethylene Glycols by Phenylchloroformates and Modification of Ribonuclease and Superoxide Dismutase," <i>Applied Biochemistry and Biotechnology,</i> 11 :141-152 (1985).
33	Woghiren et al., "Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification," Bioconjugate Chem., 4:314-318 (1993).
34	Wong, S.S. and Wong, L.J. Chemical crosslinking and the stabilization of proteins and enzymes. <i>Enzyme Microb. Technol.</i> 14 :866-874 (1992).
35	Zalipsky et al., "Attachment of Drugs to Polyethylene Glycols," Eur. Polym. J., 19(12):1177-1183 (1983).
36	Zalipsky, "Chemistry of polyethylene glycol conjugates with biologically active molecules", <i>Advanced Drug Delivery Reviews</i> , 16 :157-182 (1995).
37	Product description from Shearwater Polymers, Inc., pp. 2-49. (1995).
38	Catalog of "Polyethylene Glycol Derivatives" from Shearwater Polymers, Inc.; pp. 1-53 (1997-1998).
39	Catalog of "Polyethylene Glycol and Derivatives" from Shearwater Polymers, Inc., pp. 1-50 (2000).
40	Catalog of "Polyethylene Glycol and Derivatives for Biomedical Applications" from Shearwater Polymers, Inc., pp. 1-17 (2001)
41	Nektar Molecule Engineering Catalog of "Polyethylene Glycol Derivatives for Advanced PEGylation", pp. 1-21 (2003).
42	Catalog of "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals" from NOF Corporation; pp. 1-46 (2003, 1 st ed).
43	Catalog of "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals" from NOF Corporation; pp. 1-50 (2003, 2 nd ed).

EXAMINER		DATE CONSIDERED
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformat considered. Include copy of this form with next communication to a	nce with MPEP 609. Draw line through citation if not in conformance and not pulication(s).